<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129344">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01773876</url>
  </required_header>
  <id_info>
    <org_study_id>1126</org_study_id>
    <secondary_id>2011-005451-14</secondary_id>
    <nct_id>NCT01773876</nct_id>
  </id_info>
  <brief_title>Empirical Antifungal Treatment in ICUS</brief_title>
  <acronym>EMPIRICUS</acronym>
  <official_title>Micafungin Versus Placebo in the Nosocomial Sepsis in Patients Multi-colonized With Candida, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Invasive Candida infections are burdened with a high mortality rate and is very common in
      intensive care units. This study aims to evaluate the efficacy of empirical treatment with
      micafungin in adult patients with suspected invasive candidiasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, randomized, double-blind parallel groups comparing adult patients with
      suspected invasive candidiasis input from a 14-day empirical treatment with micafungin
      (MYCAMINE 100 mg) with placebo on survival without invasive candidiasis in 28 days after
      initiation of study treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>survival to 28 days without proven fungal infection (a fungal infection occurring within 48 hours after inclusion will be considered available for inclusion)</measure>
    <time_frame>28 days follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>breakthrough infection defined as a proven infection occurs at least 48 hours after initiation of treatment Proven infection is considered purchased after enrollment if the first significant positive levy occurs after the 48 th hour after enrollment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetic parameters: estimated gross exposure indices: AUC, Cmax, Cmin</measure>
    <time_frame>during  24 hours (between the two first infusions)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reports AUC / MIC and Cmax / MIC will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of tolerance</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>For all patients who received at least one dose of treatment:
number of adverse events reported after randomization up to 28 days, only death will count up to 3 months post-randomization (information on the long-term survival collected by telephone),
changes in the clinical examination, vital signs and laboratory results,
overall survival defined as the time from randomization to date of death from any cause.
Changes in liver function tests (bilirubin, ALT, AST, rate prothrombin, alkaline phosphatase) at the end of treatment and at the end study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacodynamic parameters: potential serum biomarkers of treatment efficacy (PCR Candida,1,3 β-D-glucan,mannan antigenemia,anti-mannan,Procalcitonin (proCT))</measure>
    <time_frame>during 28 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacodynamic parameters: Early prognostic factors of response: J7 survival without proven invasive candidiasis</measure>
    <time_frame>during 14 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of empiric treatment with micafungin in patients with invasive candidiasis possible on all-cause mortality at day 28 (end of study) and J90 (3 months post-randomization)</measure>
    <time_frame>during 90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of empiric treatment with micafungin in patients with invasive candidiasis can free survival antifungal treatment at day 28</measure>
    <time_frame>during 28 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of empiric treatment with micafungin in patients with invasive candidiasis possible evolution of organ failure during the study</measure>
    <time_frame>during 90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of empiric treatment with micafungin in patients with invasive candidiasis possible the use of mechanical ventilation during the study</measure>
    <time_frame>during 90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of empiric treatment with micafungin in patients with invasive candidiasis possible evolution of the colonization index during study</measure>
    <time_frame>during 90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of empiric treatment with micafungin in patients with invasive candidiasis possible changes in serum biomarkers (1-3 β-D-glucan, mannan antigenemia, anti-mannan Candida PCR) during the study</measure>
    <time_frame>during 90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of empiric treatment with micafungin in patients with invasive candidiasis possible on the incidence of pneumonia acquired bacterial mechanical ventilation (VAP).</measure>
    <time_frame>during 90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Invasive Candidiasis</condition>
  <arm_group>
    <arm_group_label>Micafungin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MYCAMINE 100 mg intravenous an injection of 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chlorides 100ml infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micafungin</intervention_name>
    <description>MYCAMINE 100 mg intravenous 100 mg of powder reconstituted in a 100 ml infusion bag of sodium chloride 0.9%
infusion over 24 hours for 14 days discontinuation of treatment if proven invasive candidiasis</description>
    <arm_group_label>Micafungin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>solution of sodium chloride 0.9% 100 ml for intravenous infusion infusion over 24 hours for 14 days discontinuation of placebo if proven invasive candidiasis</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Persistent sepsis without documented invasive candidiasis:

        systemic inflammatory response syndrome (SIRS) presence of two signs on the 4 [temperature
        &lt;36 ° C or&gt; 38 ° C, heart rate&gt; 90/min, respiratory rate&gt; 20/min or PaCO2 &lt;32 mmHg,
        leukocytosis&gt; 12,000 / mm3, &lt;4.000/mm3 or presence of circulating immature forms (&gt; 10% of
        cells)] mechanical ventilation (intubation or tracheostomy) for over 4 days (96 hours)
        central line use of broad-spectrum antibacterial for more than 4 calendar days (96 hours)
        in the previous week presence of at least one extra-digestive site colonized by Candida
        sp. (Urine, mouth, throat, upper and lower respiratory tract, skin folds, and suction
        drains after surgery ...), not lower digestive tract, are not taken into account the
        positive samples of rectal swabs and / or stool cultures, absence of proven bacterial
        infections untreated no evidence of invasive fungal infections (positive blood culture,
        positive culture of a surgical site, deep biopsy with fungal) infection or mold according
        to the criteria of the group &quot;fungal infection of the EORTC&quot; organ failure

          -  Hospitalization in intensive care for over 5 days (120 hours)

          -  Giving a free, informed and in writing. In the absence of the person of trust or a
             family member (if present)consent to emergency possible.

          -  Receiving a social security system,

          -  Negative pregnancy test for patients of childbearing age

        Exclusion Criteria:

          -  Proven invasive fungal infection (positive blood culture, positive culture of a
             surgical site, deep biopsy with fungal infection), including aspergillosis requiring
             antifungal therapy at the time of randomization

          -  Prognosis of less than 48 hours (for which the patient outcome will be fatal whatever
             treatment),

          -  Echinocandin antifungal treatment by more than one day or another antifungal for over
             72 hours in the week before the inclusion visit,

          -  Allergy, hypersensitivity or known intolerance to echinocandins antifungal or any of
             the excipients of the drug

          -  Neutropenia (ANC &lt;500/mm3)

          -  History of organ and bone marrow,

          -  Recent chemotherapy (less than 6 months)

          -  Systemic immunosuppressive therapy in progress, other than with corticosteroids at
             doses below 2 mg / kg / day of prednisolone or equivalent

          -  Participation in another interventional study in the same ICU stay or making
             treatment being evaluated within 28 days prior to randomization

          -  Any clinical investigator deems incompatible with the conduct of the study in
             acceptable security conditions

          -  Pregnant and lactating women,

          -  Adults subject to a legal protection measure

          -  Persons deprived of their liberty by a judicial or administrative decision, those
             hospitalized without consent, persons admitted to a health facility or social
             purposes other than research
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>TIMSIT JFT Jean François, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean Francois JFT TIMSIT, PU-PH</last_name>
    <phone>00 33 4 76 76 87 79</phone>
    <email>JFTimsit@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Khadija KH HAMMI, engineer hospital</last_name>
    <phone>00 33 4 76 76 71 09</phone>
    <email>KHammi@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Aix en Provence</name>
      <address>
        <city>Aix en Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier OB BALDESI, Dr</last_name>
      <phone>0033442335024</phone>
      <email>obaldesi@ch-aix.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier OB BALDESI, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital University of Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Christophe JCN NAVELLOU, Dr</last_name>
      <phone>0033381668127</phone>
      <email>jcnavellou@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Christophe JCN NAVELLOU, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Avicennes</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yves YC COHEN, dr</last_name>
      <phone>0033148955249</phone>
      <email>yves.cohen@avc.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Yves YC COHEN, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital University of Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Didier DG GRUSON, Dr</last_name>
      <phone>0033556795517</phone>
      <email>didier.gruson@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Didier DG GRUSON, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital University of Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bertrand BS SOUWEINE, PU-PH</last_name>
      <phone>0033473754983</phone>
      <email>bsouweine@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Bertrand BS SOUWEINE, Pu-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine CPB PAUGAM-BURTZ, Dr</last_name>
      <phone>0033140875911</phone>
      <email>catherine.paugam@bjn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine CPB PAUGAM-BURTZ, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Emmanuel PEC CHARLES, Dr</last_name>
      <phone>0033380293751</phone>
      <email>pierre-emmanuel.charles@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Emmanuel PEC CHARLES, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of Draguignan</name>
      <address>
        <city>Draguignan</city>
        <zip>83300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas NB BELE, Dr</last_name>
      <phone>0033494605071</phone>
      <email>nicolasbele@free.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas NB BELE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Riyad RF FARHAT, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital University of Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Francois JFT TIMSIT, PU-PH</last_name>
      <phone>0033476768779</phone>
      <email>JFTimsit@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Francois JFT TIMSIT, Pu-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rebecca RH HAMDIFAR-ROY, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of Versailles</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BRUNEEL BF Fabrice, Dr</last_name>
      <phone>0033139638842</phone>
      <email>FBRUNEEL@ch-versailles.fr</email>
    </contact>
    <investigator>
      <last_name>BRUNEEL BF Fabrice, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>96433</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ARGAUD AL Laurent, Dr</last_name>
      <phone>0033472110015</phone>
      <email>laurent.argaud@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Argaud AL Laurent, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>96433</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard BA ALLAOUCHICHE, PU-PH</last_name>
      <phone>0033472116988</phone>
      <email>bernard.allaouchiche@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Bernard BA ALLAOUCHICHE, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital University of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kada KK KLOUCHE, dr</last_name>
      <phone>0033467338438</phone>
      <email>k-klouche@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Kada KK KLOUCHE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital University of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samir SJ JABER, Dr</last_name>
      <phone>0033467337271</phone>
      <email>s-jaber@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Samir SJ JABER, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Interegional Hospital André Grégoire</name>
      <address>
        <city>Montreuil</city>
        <zip>93105</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent VD DAS, Dr</last_name>
      <phone>0033149203073</phone>
      <email>vincent.das@chi-andregregoire.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent VD DAS, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magali MC CIROLDI, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of La Pitié Salpetrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean JC CHASTRE, PU-PH</last_name>
      <phone>0033142163821</phone>
      <email>jean.chastre@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jean JC CHASTRE, Pu-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital University of Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel MW WOLFF, PU-PH</last_name>
      <phone>0033140258123</phone>
      <email>michel.wolff@bch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Michel MW WOLFF, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital St Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard BM MISSET, Dr</last_name>
      <phone>0033144123415</phone>
      <email>bmisset@hospital-saint-joseph.org</email>
    </contact>
    <investigator>
      <last_name>Bernard BM MISSET, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit BS SCHLEMMER, PU-PH</last_name>
      <phone>0033142499421</phone>
      <email>benoir.schlemmer@sls.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Benoit BS SCHLEMMER, Pu-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elie EA AZOULAY, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of Pontoise</name>
      <address>
        <city>Pontoise</city>
        <zip>95303</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Danièle DC COMBAUX, Dr</last_name>
      <phone>0033130754104</phone>
      <email>daniel.combaux@ch-pontoise.fr</email>
    </contact>
    <investigator>
      <last_name>Danièle dc COMBAUX, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital University of Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joel JC COUSSON, Dr</last_name>
      <phone>0033326783022</phone>
      <email>jcousson@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Joel JC COUSSON, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Departemental Hospital of Roche sur Yon</name>
      <address>
        <city>Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean JR REIGNIER, Dr</last_name>
      <phone>00 332 51 44 61 61</phone>
      <email>reanimation@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Jean JR REIGNIER, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabrice FZ ZENI, PU-PH</last_name>
      <phone>0033477127862</phone>
      <email>zeni@univ-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Fabrice FZ ZENI, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ferhat FM MEZIANI, Dr</last_name>
      <phone>0033388116768</phone>
      <email>ferhat.meziani@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Ferhat FM MEZIANI, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David DS SCHNELL, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 29, 2013</lastchanged_date>
  <firstreceived_date>January 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>survival without proven invasive candidiasis</keyword>
  <keyword>effectiveness</keyword>
  <keyword>micafungin versus placebo</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>pharmacodynamic</keyword>
  <keyword>tolerance</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Invasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Micafungin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
